Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tabernero

Showing results (11-20 of 1,740) with videos related to

Pageof 174
Sort By:
Eye (London, England)|November 11, 2017
SIA-formula: an easy way to calculate surgically induced astigmatismS Sánchez-Tabernero
Open Respiratory Archives|June 14, 2024
[Advances and Challenges in Multidrug Resistant Tuberculosis (MDR-TB) Control]Eva Tabernero Huguet
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
CardiotoxicityI Brana, J Tabernero
Current Clinical Pharmacology|April 22, 2010
Monoclonal antibodies in solid tumoursBen Markman, Josep Tabernero
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical developmentJosep Tabernero, Teresa Macarulla
Nature Reviews. Clinical Oncology|June 15, 2016
Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRCJosep Tabernero, Ramon Salazar
Cancer Cell|December 15, 2020
The Effective Targeting of KRAS<sup>G12C</sup> ElusivenessElena Elez, Josep Tabernero
JACC. Cardiooncology|August 16, 2021
Back-to-Back Discovery, Co-Precision, and PreventionBarbara Casadei, Josep Tabernero
Cancer Discovery|July 8, 2017
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the DarknessJordi Rodon, Josep Tabernero
JAMA Oncology|February 4, 2021
Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-ReplyKohei Shitara, Josep Tabernero
Pageof 174

Showing results (11-20 of 1,740) with videos related to

Sort By:
Pageof 174
Eye (London, England)|November 11, 2017
SIA-formula: an easy way to calculate surgically induced astigmatismS Sánchez-Tabernero
Open Respiratory Archives|June 14, 2024
[Advances and Challenges in Multidrug Resistant Tuberculosis (MDR-TB) Control]Eva Tabernero Huguet
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
CardiotoxicityI Brana, J Tabernero
Current Clinical Pharmacology|April 22, 2010
Monoclonal antibodies in solid tumoursBen Markman, Josep Tabernero
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical developmentJosep Tabernero, Teresa Macarulla
Nature Reviews. Clinical Oncology|June 15, 2016
Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRCJosep Tabernero, Ramon Salazar
Cancer Cell|December 15, 2020
The Effective Targeting of KRAS<sup>G12C</sup> ElusivenessElena Elez, Josep Tabernero
JACC. Cardiooncology|August 16, 2021
Back-to-Back Discovery, Co-Precision, and PreventionBarbara Casadei, Josep Tabernero
Cancer Discovery|July 8, 2017
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the DarknessJordi Rodon, Josep Tabernero
JAMA Oncology|February 4, 2021
Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-ReplyKohei Shitara, Josep Tabernero
Pageof 174